Ohr Pharma's eye drug fails main goal in mid-stage study

March 27 (Reuters) - Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares down 21 percent in premarket trading on Friday.